The observation that CIC is often heavily infiltrated by CD8 + T cell and CD4 + T cells raises the question whether T cell–selective agents including tacrolimus, cyclosporine, or ustekinumab that are used in aGVHD and IBD may be beneficial in CIC treatment [36–38]. The gene discussed is CD8A; the disease is inflammatory bowel disease.